Nanomedicine for tumor therapy-current status and challenges

doi:10.5246/jcps.2021.05.029

Abstract

Abstract:

The field of nanomedicine in controlled drug delivery systems, especially for tumor targeting, has tremendously progressed over the past decades because of its plentiful benefits, such as biocompatibility, stability in blood circulation, and ability to reduce side effects. Although a large number of relevant papers are published every year, few nanodrugs are available for clinical treatment. The present review aimed to explore the barriers in nanomedicine delivery and tumor targeting. Rational design of nanomedicine should consider not only tumor heterogeneity, in vivo metabolism, and physicochemical properties, but also more efficient innovations in particulate formulations for clinical application.

Key words: Nanomedicine, Tumor heterogeneity, Nano-delivery, Enhanced permeability and retention effects

Supporting:

Jinglei Wang, Ke Song, Hao Pan, Yang Liu, Dazhuang Wang, Lijian Chen. Nanomedicine for tumor therapy-current status and challenges[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(5): 359-380.

Figures/Tables 4

References 131

[1]	Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release. 2000, 65, 271–284.
[2]	Divsalar, A.; Saboury, A.A.; Nabiuni, M.; Zare, Z.; Kefayati, M.E.; Seyedarabi, A. Characterization and side effect analysis of a newly designed nanoemulsion targeting human serum albumin for drug delivery. Colloids Surf. B Biointerfaces. 2012, 98, 80–84.
[3]	Wang, X.L.; Liang, Y.Q.; Zhang, Y.; He, B.; Dai, W.B.; Zhang, H.; Wang, X.Q.; Zhang, Q. Combination therapy of cRGD-DOX self-assembled nanoparticles and bevacizumab for breast cancer. J. Chin. Pharm. Sci. 2019, 28, 627–640.
[4]	Benizri, S.; Ferey, L.; Alies, B.; Mebarek, N.; Vacher, G.; Appavoo, A.; Staedel, C.; Gaudin, K.; Barthélémy, P. Nucleoside-lipid-based nanocarriers for sorafenib delivery. Nanoscale Res. Lett. 2018, 13, 17.
[5]	Abdellatif, A.A.H.; El-Telbany, D.F.A.; Zayed, G.; Al-Sawahli, M.M. Hydrogel containing PEG-coated fluconazole nanoparticles with enhanced solubility and antifungal activity. J. Pharm. Innov. 2019, 14, 112–122.
[6]	Xia, Y.; Xu, T.T.; Wang, C.B.; Li, Y.H.; Lin, Z.F.; Zhao, M.Q.; Zhu, B. Novel functionalized nanoparticles for tumor-targeting co-delivery of doxorubicin and siRNA to enhance cancer therapy. Int. J. Nanomed. 2017, 13, 143–159.
[7]	Field, L.D.; Walper, S.A.; Susumu, K.; Lasarte-Aragones, G.; Oh, E.; Medintz, I.L.; Delehanty, J.B. A quantum dot-protein bioconjugate that provides for extracellular control of intracellular drug release. Bioconjug. Chem. 2018, 29, 2455–2467.
[8]	Attari, Z.; Kalvakuntla, S.; Reddy, M.S.; Deshpande, M.; Rao, C.M.; Koteshwara, K.B. Formulation and characterisation of nanosuspensions of BCS class II and IV drugs by combinative method. J. Exp. Nanosci. 2016, 11, 276–288.
[9]	Xiao, H.H.; Song, H.Q.; Yang, Q.; Cai, H.D.; Qi, R.G.; Yan, L.S.; Liu, S.; Zheng, Y.H.; Huang, Y.B.; Liu, T.J.; Jing, X.B. A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance. Biomaterials. 2012, 33, 6507–6519.
[10]	Lu, X.; Wang, Q.Q.; Xu, F.J.; Tang, G.P.; Yang, W.T. A cationic prodrug/therapeutic gene nanocomplex for the synergistic treatment of tumors. Biomaterials. 2011, 32, 4849–4856.
[11]	Sun, J.J.; Liu, Y.H.; Chen, Y.C.; Zhao, W.C.; Zhai, Q.Y.; Rathod, S.; Huang, Y.X.; Tang, S.Q.; Kwon, Y.T.; Fernandez, C.; Venkataramanan, R.; Li, S. Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy. J. Control. Release. 2017, 258, 43–55.
[12]	Kaur, A.; Jyoti, K.; Baldi, A.; Jain, U.K.; Chandra, R.; Madan, J. Self-assembled nanomicelles of amphiphilic clotrimazole glycyl-glycine analogue augmented drug delivery, apoptosis and restrained melanoma tumour progression. Mater. Sci. Eng. C Mater. Biol. Appl. 2018, 89, 75–86.
[13]	Fan, Y.C.; Du, W.W.; He, B.; Fu, F.Y.; Yuan, L.; Wu, H.N.; Dai, W.B.; Zhang, H.; Wang, X.Q.; Wang, J.C.; Zhang, X.; Zhang, Q. The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin. Biomaterials. 2013, 34, 2277–2288.
[14]	Jin, H.L.; Wan, C.; Zou, Z.W.; Zhao, G.F.; Zhang, L.L.; Geng, Y.Y.; Chen, T.; Huang, A.; Jiang, F.G.; Feng, J.P.; Lovell, J.F.; Chen, J.; Wu, G.; Yang, K.Y. Tumor ablation and therapeutic immunity induction by an injectable peptide hydrogel. ACS Nano. 2018, 12, 3295–3310.
[15]	Geng, H.J.; Zhao, Y.T.; Liu, J.; Cui, Y.; Wang, Y.; Zhao, Q.F.; Wang, S.L. Hollow mesoporous silica as a high drug loading carrier for regulation insoluble drug release. Int. J. Pharm. 2016, 510, 184–194.
[16]	Li, J.; Liang, X.; Zhang, J.; Yin, Y.Z.; Zuo, T.T.; Wang, Y.Y.; Yang, X.M.; Shen, Q. Inhibiting pulmonary metastasis of breast cancer based on dual-targeting graphene oxide with high stability and drug loading capacity. Nanomed. Nanotechnol. Biol. Med. 2018, 14, 1237–1248.
[17]	Heister, E.; Neves, V.; Lamprecht, C.; Silva, S.R.P.; Coley, H.M.; McFadden, J. Drug loading, dispersion stability, and therapeutic efficacy in targeted drug delivery with carbon nanotubes. Carbon. 2012, 50, 622–632.
[18]	Bianco, A. Graphene: safe or toxic? the two faces of the medal. Angew. Chem. Int. Ed. 2013, 52, 4986–4997.
[19]	Niikura, K.; Iyo, N.; Matsuo, Y.; Mitomo, H.; Ijiro, K. Sub-100 nm gold nanoparticle vesicles as a drug delivery carrier enabling rapid drug release upon light irradiation. ACS Appl. Mater. Interfaces. 2013, 5, 3900–3907.
[20]	Li, J.C.; Hu, Y.; Yang, J.; Wei, P.; Sun, W.J.; Shen, M.W.; Zhang, G.X.; Shi, X.Y. Hyaluronic acid-modified Fe₃O₄@Au core/shell nanostars for multimodal imaging and photothermal therapy of tumors. Biomaterials. 2015, 38, 10–21.
[21]	Almeida, J.P.M.; Chen, A.L.; Foster, A.; Drezek, R. In vivo biodistribution of nanoparticles. Nanomedicine. 2011, 6, 815–835.
[22]	Gao, M.; Liang, C.; Song, X.J.; Chen, Q.; Jin, Q.T.; Wang, C.; Liu, Z. Erythrocyte-membrane-enveloped perfluorocarbon as nanoscale artificial red blood cells to relieve tumor hypoxia and enhance cancer radiotherapy. Adv. Mater. 2017, 29, 1701429.
[23]	Farooqi, A.A.; Desai, N.N.; Qureshi, M.Z.; Librelotto, D.R.N.; Gasparri, M.L.; Bishayee, A.; Nabavi, S.M.; Curti, V.; Daglia, M. Exosome biogenesis, bioactivities and functions as new delivery systems of natural compounds. Biotechnol. Adv. 2018, 36, 328–334.
[24]	Tang, B.; Fang, G.H.; Gao, Y.; Liu, Y.; Liu, J.W.; Zou, M.J.; Wang, L.H.; Cheng, G. Lipid-albumin nanoassemblies co-loaded with borneol and paclitaxel for intracellular drug delivery to C6 glioma cells with P-gp inhibition and its tumor targeting. Asian J. Pharm. Sci. 2015, 10, 363–371.
[25]	Zhu, J.Y.; Zheng, D.W.; Zhang, M.K.; Yu, W.Y.; Qiu, W.X.; Hu, J.J.; Feng, J.; Zhang, X.Z. Preferential cancer cell self-recognition and tumor self-targeting by coating nanoparticles with homotypic cancer cell membranes. Nano Lett. 2016, 16, 5895–5901.
[26]	Zhou, C.H.; Hu, X.P.; Liu, Q.; Wang, L.Q.; Zhou, Y.H.; Jin, Y.; Liu, Y. Enhanced tumor-targeted delivery of anticancer drugs by folic acid-conjugated pH-sensitive polymeric micelles. J. Chin. Pharm. Sci. 2020, 29, 626–636.
[27]	Meng, H.; Zhao, Y.; Dong, J.Y.; Xue, M.; Lin, Y.S.; Ji, Z.X.; Mai, W.X.; Zhang, H.Y.; Chang, C.H.; Brinker, C.J.; Zink, J.I.; Nel, A.E. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. ACS Nano. 2013, 7, 10048–10065.
[28]	Araki, T.; Ogawara, K.I.; Suzuki, H.; Kawai, R.E.; Watanabe, T.I.; Ono, T.; Higaki, K. Augmented EPR effect by photo-triggered tumor vascular treatment improved therapeutic efficacy of liposomal paclitaxel in mice bearing tumors with low permeable vasculature. J. Control. Release. 2015, 200, 106–114.
[29]	Wicki, A.; Witzigmann, D.; Balasubramanian, V.; Huwyler, J. Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications. J. Control. Release. 2015, 200, 138–157.
[30]	Park, K. Facing the truth about nanotechnology in drug delivery. ACS Nano. 2013, 7, 7442–7447.
[31]	Etheridge, M.L.; Campbell, S.A.; Erdman, A.G.; Haynes, C.L.; Wolf, S.M.; McCullough, J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomed. Nanotechnol. Biol. Med. 2013, 9, 1–14.
[32]	Lammers, T.; Kiessling, F.; Hennink, W.E.; Storm, G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J. Control. Release. 2012, 161, 175–187.
[33]	Meacham, C.E.; Morrison, S.J. Tumour heterogeneity and cancer cell plasticity. Nature. 2013, 501, 328–337.
[34]	Marte, B. Tumour heterogeneity. Nature. 2013, 501, 327.
[35]	Straussman, R.; Morikawa, T.; Shee, K.; Barzily-Rokni, M.; Golub, T.R. Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion. Nature. 2012, 487, 500–504.
[36]	Gkolfinopoulos, S.; Mountzios, G. Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer. Ann. Transl. Med. 2018, 6, 142.
[37]	Hanibuchi, M.; Kim, S.J.; Fidler, I.J.; Nishioka, Y. The molecular biology of lung cancer brain metastasis: an overview of current comprehensions and future perspectives. J. Med. Invest. 2014, 61, 241–253.
[38]	Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998, 351, 1451–1467.
[39]	Hondermarck, H.; Vercoutter-Edouart, A.S.; Révillion, F.; Lemoine, J.; El-Yazidi-belkoura, I.; Nurcombe, V.; Peyrat, J.P. Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics. 2001, 1, 1216–1232.
[40]	Petty, R.D.; Dahle-Smith, A.; Miedzybrodzka, Z.; Dutton, S.J.; Murray, G.I.; Stevenson, D.; Massie, D.; Osbourne, A.; Clark, C.; Mansoor, W.; Thompson, J.; Harrison, M.; Chatterjee, A.; Falk, S.; Elyan, S.; Garcia-Alonso, A.; Fyfe, D.W.; Chau, I.; Collinson, D.; Ferry, D. Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): Results of a biomarker analysis of a phase III trial of gefitinib versus placebo (TRANS-COG). J. Clin. Oncol. 2014, 32, 4016.
[41]	Friedl, P.; Wolf, K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer. 2003, 3, 362–374.
[42]	Zhao, G.B.; Zhu, G.W.; Huang, Y.J.; Zheng, W.; Hua, J.; Yang, S.G.; Zhuang, J.F.; Ye, J.X. IL-6 mediates the signal pathway of JAK-STAT3-VEGF-C promoting growth, invasion and lymphangiogenesis in gastric cancer. Oncol. Rep. 2016, 35, 1787–1795.
[43]	Sukawa, Y.; Yamamoto, H.; Nosho, K.; Ito, M.; Igarashi, H.; Naito, T.; Mitsuhashi, K.; Matsunaga, Y.; Takahashi, T.; Mikami, M.; Adachi, Y.; Suzuki, H.; Shinomura, Y. HER2 expression and PI₃K-Akt pathway alterations in gastric cancer. Digestion. 2014, 89, 12–17.
[44]	Okano, J.I.; Nagahara, T.; Matsumoto, K.; Murawaki, Y. The growth inhibition of liver cancer cells by paclitaxel and the involvement of extracellular signal-regulated kinase and apoptosis. Oncol. Rep. 2007, 1, 1195–1200.
[45]	Escudier, B.; Eisen, T.; Stadler, W.M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A.A.; Rolland, F.; Demkow, T.; Hutson, T.E.; Gore, M.; Freeman, S.; Schwartz, B.; Shan, M.; Simantov, R.; Bukowski, R.M. Sorafenib in advanced clear-cell renal-cell carcinoma. Uro. Oncol. Semin. Original Invest. 2007, 356, 125–34.
[46]	Jain, R.K.; Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 2010, 7, 653–664.
[47]	Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release. 2000, 65, 271–284.
[48]	Hodkinson, P.S.; MacKinnon, A.C.; Sethi, T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Int. J. Radiat. Biol. 2007, 83, 733–741.
[49]	Frisch, S.M.; Francis, H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 1994, 124, 619–626.
[50]	Miao, L.; Huang, L. Exploring the tumor microenvironment with nanoparticles. Cancer Treat. Res. 2015, 166, 193–226.
[51]	Liu, S.; Agalliu, D.; Yu, C.H.; Fisher, M. The role of pericytes in blood-brain barrier function and stroke. Curr. Pharm. Des. 2012, 18, 3653–3662.
[52]	Danhier, F. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? J. Control. Release. 2016, 244, 108–121.
[53]	Zhang, L.Z.; Nishihara, H.; Kano, M.R. Pericyte-coverage of human tumor vasculature and nanoparticle permeability. Biol. Pharm. Bull. 2012, 35, 761–766.
[54]	Kano, M.R. Nanotechnology and tumor microcirculation. Adv. Drug Deliv. Rev. 2014, 74, 2–11.
[55]	Kanomata, N. Impact of tumor size on the clinical outcomes of patients with Robson Stage I renal cell carcinoma. Cancer. 1999, 86, 545–546.
[56]	Zhou, W.C.; Chen, C.; Shi, Y.; Wu, Q.L.; Gimple, R.C.; Fang, X.G.; Huang, Z.; Zhai, K.; Ke, S.Q.; Ping, Y.F.; Feng, H.; Rich, J.N.; Yu, J.S.; Bao, S.D.; Bian, X.W. Targeting glioma stem cell-derived pericytes disrupts the blood-tumor barrier and improves chemotherapeutic efficacy. Cell Stem Cell. 2017, 21, 591–603.e4.
[57]	Kano, M.R.; Komuta, Y.; Iwata, C.; Oka, M.; Shirai, Y.T.; Morishita, Y.; Ouchi, Y.; Kataoka, K.; Miyazono, K. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-β receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci. 2009, 100, 173–180.
[58]	Kano, M.R. Nanotechnology and tumor microcirculation. Adv. Drug Deliv. Rev. 2014, 74, 2–11.
[59]	Bose, A.; Barik, S.; Banerjee, S.; Ghosh, T.; Mallick, A.; Bhattacharyya Majumdar, S.; Goswami, K.K.; Bhuniya, A.; Banerjee, S.; Baral, R.; Storkus, W.J.; Dasgupta, P.S.; Majumdar, S. Tumor-derived vascular pericytes anergize Th cells. J. Immunol. 2013, 191, 971–981.
[60]	Ensign, L.M.; Cone, R.; Hanes, J. Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 2012, 64, 557–570.
[61]	Fröhlich, E.; Roblegg, E. Mucus as barrier for drug delivery by nanoparticles. J. Nanosci. Nanotechnol. 2014, 14, 126–136.
[62]	Hurkat, P.; Jain, A.; Jain, A.; Shilpi, S.; Gulbake, A.; Jain, S.K. Concanavalin A conjugated biodegradable nanoparticles for oral insulin delivery. J. Nanopart. Res. 2012, 14, 1219.
[63]	Jain, S.; Rathi, V.V.; Jain, A.K.; Das, M.; Godugu, C. Folate-decorated PLGA nanoparticles as a rationally designed vehicle for the oral delivery of insulin. Nanomedicine. 2012, 7, 1311–1337.
[64]	Tian, B.S.; Liu, S.H.; Wu, S.Y.; Lu, W.; Wang, D.; Jin, L.; Hu, B.; Li, K.; Wang, Z.L.; Quan, Z.W. pH-responsive poly (acrylic acid)-gated mesoporous silica and its application in oral colon targeted drug delivery for doxorubicin. Colloids Surf. B Biointerfaces. 2017, 154, 287–296.
[65]	Pi, J.X.; Wang, S.Y.; Li, W.; Kebebe, D.; Zhang, Y.; Zhang, B.; Qi, D.L.; Guo, P.; Li, N.; Liu, Z.D. A nano-cocrystal strategy to improve the dissolution rate and oral bioavailability of baicalein. Asian J. Pharm. Sci. 2019, 14, 154–164.
[66]	Aggarwal, P.; Hall, J.B.; McLeland, C.B.; Dobrovolskaia, M.A.; McNeil, S.E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 2009, 61, 428–437.
[67]	Yogasundaram, H.; Bahniuk, M.S.; Singh, H.D.; Aliabadi, H.M.; Uludaǧ, H.; Unsworth, L.D. BSA nanoparticles for siRNA delivery: coating effects on nanoparticle properties, plasma protein adsorption, and In Vitro siRNA delivery. Int. J. Biomater. 2012, 2012, 1–10.
[68]	Dutta, D.; Sundaram, S.K.; Teeguarden, J.G.; Riley, B.J.; Fifield, L.S.; Jacobs, J.M.; Addleman, S.R.; Kaysen, G.A.; Moudgil, B.M.; Weber, T.J. Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials. Toxicol. Sci. 2007, 100, 303–315.
[69]	Diederichs, J.E. Plasma protein adsorption patterns on liposomes: Establishment of analytical procedure. Electrophoresis. 1996, 17, 607–611.
[70]	Hu, Z.Y.; Zhang, H.Y.; Zhang, Y.; Wu, R.A.; Zou, H.F. Nanoparticle size matters in the formation of plasma protein coronas on Fe₃O₄ nanoparticles. Colloids Surf. B Biointerfaces. 2014, 121, 354–361.
[71]	Zuckerman, J.E.; Davis, M.E. Targeting therapeutics to the glomerulus with nanoparticles. Adv. Chronic Kidney Dis. 2013, 20, 500–507.
[72]	Zuckerman, J.E.; Choi, C.H.J.; Han, H.; Davis, M.E. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. PNAS. 2012, 109, 3137–3142.
[73]	Liu, J.B.; Yu, M.X.; Zhou, C.; Zheng, J. Renal clearable inorganic nanoparticles: a new frontier of bionanotechnology. Mater. Today. 2013, 16, 477–486.
[74]	Soo Choi, H.; Liu, W.H.; Misra, P.; Tanaka, E.; Zimmer, J.P.; Itty Ipe, B.; Bawendi, M.G.; Frangioni, J.V. Renal clearance of quantum dots. Nat. Biotechnol. 2007, 25, 1165–1170.
[75]	Gómez-Vallejo, V.; Puigivila, M.; Plaza-García, S.; Szczupak, B.; Piñol, R.; Murillo, J.L.; Sorribas, V.; Lou, G.; Veintemillas, S.; Ramos-Cabrer, P.; Llop, J.; Millán, A. PEG-copolymer-coated iron oxide nanoparticles that avoid the reticuloendothelial system and act as kidney MRI contrast agents. Nanoscale. 2018, 10, 14153–14164.
[76]	Colombo, C.; Li, M.; Watanabe, S.; Messa, P.; Edefonti, A.; Montini, G.; Moscatelli, D.; Rastaldi, M.P.; Cellesi, F. Polymer nanoparticle engineering for podocyte repair: from in vitro models to new nanotherapeutics in kidney diseases. ACS Omega. 2017, 2, 599–610.
[77]	Brannon-Peppas, L.; Blanchette, J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 2004, 56, 1649–1659.
[78]	Kobayashi, H.; Watanabe, R.; Choyke, P.L. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics. 2013, 4, 81–89.
[79]	Jung, B.; Shim, M.K.; Park, M.J.; Jang, E.H.; Yoon, H.Y.; Kim, K.; Kim, J.H. Hydrophobically modified polysaccharide-based on polysialic acid nanoparticles as carriers for anticancer drugs. Int. J. Pharm. 2017, 520, 111–118.
[80]	Kim, Y.H.; Min, K.H.; Wang, Z.T.; Kim, J.; Jacobson, O.; Huang, P.; Zhu, G.Z.; Liu, Y.J.; Yung, B.; Niu, G.; Chen, X.Y. Development of sialic acid-coated nanoparticles for targeting cancer and efficient evasion of the immune system. Theranostics. 2017, 7, 962–973.
[81]	Yin, J.T.; Wang, P.Q.; Yin, Y.Y.; Hou, Y.T.; Song, X.Y. Optimization on biodistribution and antitumor activity of tripterine using polymeric nanoparticles through RES saturation. Drug Deliv. 2017, 24, 1891–1897.
[82]	Yue, J.; Wang, Z.; Shao, D.; Chang, Z.M.; Hu, R.; Li, L.; Luo, S.Z.; Dong, W.F. Cancer cell membrane-modified biodegradable mesoporous silica nanocarriers for berberine therapy of liver cancer. RSC Adv. 2018, 8, 40288–40297.
[83]	Aoyama, M.; Hata, K.; Higashisaka, K.; Nagano, K.; Yoshioka, Y.; Tsutsumi, Y. Clusterin in the protein corona plays a key role in the stealth effect of nanoparticles against phagocytes. Biochem. Biophys. Res. Commun. 2016, 480, 690–695.
[84]	CM de Lange, E. The physiological characteristics and transcytosis mechanisms of the blood-brain barrier (BBB). Curr. Pharm. Biotechnol. 2012, 13, 2319–2327.
[85]	Song, Z.H.; Liu, T.; Chen, T.F. Overcoming blood–brain barrier by HER2-targeted nanosystem to suppress glioblastoma cell migration, invasion and tumor growth. J. Mater. Chem. B. 2018, 6, 568–579.
[86]	Chai, Z.L.; Hu, X.F.; Wei, X.L.; Zhan, C.Y.; Lu, L.W.; Jiang, K.; Su, B.X.; Ruan, H.T.; Ran, D.N.; Fang, R.H.; Zhang, L.F.; Lu, W.Y. A facile approach to functionalizing cell membrane-coated nanoparticles with neurotoxin-derived peptide for brain-targeted drug delivery. J. Control. Release. 2017, 264, 102–111.
[87]	Hajal, C.; Campisi, M.; Mattu, C.; Chiono, V.; Kamm, R.D. In vitro models of molecular and nano-particle transport across the blood-brain barrier. Biomicrofluidics. 2018, 12, 042213.
[88]	Pamies, D.; Hartung, T.; Hogberg, H.T. Biological and medical applications of a brain-on-a-chip. Exp. Biol. Med. 2014, 239, 1096–1107.
[89]	Kano, Mitsunobu R. Nanotechnology and tumor microcirculation. Adv. Drug Deliv. Rev. 2014, 74, 2–11.
[90]	Dreher, M.R.; Liu, W.G.; Michelich, C.R.; Dewhirst, M.W.; Yuan, F.; Chilkoti, A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst. 2006, 98, 335–344.
[91]	Cabral, H.; Matsumoto, Y.; Mizuno, K.; Chen, Q.; Murakami, M.; Kimura, M.; Terada, Y.; Kano, M.R.; Miyazono, K.; Uesaka, M.; Nishiyama, N.; Kataoka, K. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 2011, 6, 815–823.
[92]	Cabral, H.; Matsumoto, Y.; Mizuno, K.; Chen, Q.; Murakami, M.; Kimura, M.; Terada, Y.; Kano, M.R.; Miyazono, K.; Uesaka, M.; Nishiyama, N.; Kataoka, K. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 2011, 6, 815–823.
[93]	Chen, F.; Hong, H.; Zhang, Y.; Valdovinos, H.F.; Shi, S.X.; Kwon, G.S.; Theuer, C.P.; Barnhart, T.E.; Cai, W.B. In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles. ACS Nano. 2013, 7, 9027–9039.
[94]	Tu, Z.X.; Achazi, K.; Schulz, A.; Mülhaupt, R.; Thierbach, S.; Rühl, E.; Adeli, M.; Haag, R. Combination of surface charge and size controls the cellular uptake of functionalized graphene sheets. Adv. Funct. Mater. 2017, 27, 1701837.
[95]	Pan, Y.; Leifert, A.; Ruau, D.; Neuss, S.; Bornemann, J.; Schmid, G.; Brandau, W.; Simon, U.; Jahnen-Dechent, W. Gold nanoparticles of diameter 1.4 nm trigger necrosis by oxidative stress and mitochondrial damage. Small. 2009, 5, 2067–2076.
[96]	Oyewumi, M.O.; Kumar, A.; Cui, Z.R. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert. Rev. Vaccines. 2010, 9, 1095–1107.
[97]	Dahmani, F.Z.; Yang, H.; Zhou, J.P.; Yao, J.; Zhang, T.; Zhang, Q. Enhanced oral bioavailability of paclitaxel in pluronic/LHR mixed polymeric micelles: Preparation, in vitro and in vivo evaluation. Eur. J. Pharm. Sci. 2012, 47, 179–189.
[98]	Prasad, K.N.; Luong, T.T.; FlorenceJoelle Paris, A.T.; Vaution, C.; Seiller, M.; Puisieux, F. Surface activity and association of ABA polyoxyethylene: polyoxypropylene block copolymers in aqueous solution. J. Colloid Interface Sci. 1979, 69, 225–232.
[99]	Mohammad, A.K.; Reineke, J.J. Quantitative detection of PLGA nanoparticle degradation in tissues following intravenous administration. Mol. Pharmaceutics. 2013, 10, 2183–2189.
[100]	Bernabeu, E.; Cagel, M.; Lagomarsino, E.; Moretton, M.; Chiappetta, D.A. Paclitaxel: What has been done and the challenges remain ahead. Int. J. Pharm. 2017, 526, 474–495.
[101]	Truong, N.P.; Whittaker, M.R.; Mak, C.W.; Davis, T.P. The importance of nanoparticle shape in cancer drug delivery. Expert. Opin. Drug Deliv. 2015, 12, 129–142.
[102]	Geng, Y.; Dalhaimer, P.; Cai, S.S.; Tsai, R.; Tewari, M.; Minko, T.; Discher, D.E. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2007, 2, 249–255.
[103]	Guo, Y.F.; Zhao, S.; Qiu, H.H.; Wang, T.; Zhao, Y.N.; Han, M.H.; Dong, Z.Q.; Wang, X.T. Shape of nanoparticles as a design parameter to improve docetaxel antitumor efficacy. Bioconjug. Chem. 2018, 29, 1302–1311.
[104]	Decuzzi, P.; Lee, S.; Bhushan, B.; Ferrari, M. A theoretical model for the margination of particles within blood vessels. Ann. Biomed. Eng. 2005, 33, 179–190.
[105]	Decuzzi, P.; Pasqualini, R.; Arap, W.; Ferrari, M. Intravascular delivery of particulate systems: does geometry really matter? Pharm. Res. 2009, 26, 235–243.
[106]	Gavze, E.; Shapiro, M. Motion of inertial spheroidal particles in a shear flow near a solid wall with special application to aerosol transport in microgravity. J. Fluid Mech. 1998, 371, 59–79.
[107]	Gentile, F.; Chiappini, C.; Fine, D.; Bhavane, R.C.; Peluccio, M.S.; Cheng, M.M.C.; Liu, X.; Ferrari, M.; Decuzzi, P. The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. J. Biomech. 2008, 41, 2312–2318.
[108]	Muro, S.; Garnacho, C.; Champion, J.A.; Leferovich, J.; Gajewski, C.; Schuchman, E.H.; Mitragotri, S.; Muzykantov, V.R. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol. Ther. 2008, 16, 1450–1458.
[109]	Sun, Z.Z.; Worden, M.; Wroczynskyj, Y.; Manna, P.K.; Thliveris, J.A.; van Lierop, J.; Hegmann, T.; Miller, D.W. Differential internalization of brick shaped iron oxide nanoparticles by endothelial cells. J. Mater. Chem. B. 2016, 4, 5913–5920.
[110]	Chauhan, V.P.; Popović, Z.; Chen, O.; Cui, J.; Fukumura, D.; Bawendi, M.G.; Jain, R.K. Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew. Chem. Int. Ed. 2011, 50, 11417–11420.
[111]	Wang, Y.C.; Black, K.C.L.; Luehmann, H.; Li, W.Y.; Zhang, Y.; Cai, X.; Wan, D.H.; Liu, S.Y.; Li, M.; Kim, P.; Li, Z.Y.; Wang, L.V.; Liu, Y.J.; Xia, Y.N. Comparison study of gold nanohexapods, nanorods, and nanocages for photothermal cancer treatment. ACS Nano. 2013, 7, 2068–2077.
[112]	Nizamov, T.R.; Garanina, A.S.; Grebennikov, I.S.; Zhironkina, O.A.; Strelkova, O.S.; Alieva, I.B.; Kireev, I.I.; Abakumov, M.A.; Savchenko, A.G.; Majouga, A.G. Effect of iron oxide nanoparticle shape on doxorubicin drug delivery toward LNCaP and PC-3 cell lines. BioNanoScience. 2018, 8, 394–406.
[113]	Bhamidipati, M.; Fabris, L. Multiparametric assessment of gold nanoparticle cytotoxicity in cancerous and healthy cells: the role of size, shape, and surface chemistry. Bioconjugate Chem. 2017, 28, 449–460.
[114]	Maurer-Jones, M.A.; Lin, Y.S.; Haynes, C.L. Functional assessment of metal oxide nanoparticle toxicity in immune cells. ACS Nano. 2010, 4, 3363–3373.
[115]	Yu, T.; Malugin, A.; Ghandehari, H. Impact of silica nanoparticle design on cellular toxicity and hemolytic activity. ACS Nano. 2011, 5, 5717–5728.
[116]	He, C.B.; Hu, Y.P.; Yin, L.C.; Tang, C.; Yin, C.H. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010, 31, 3657–3666.
[117]	Liu, X.S.; Li, H.; Chen, Y.J.; Jin, Q.; Ren, K.F.; Ji, J. Mixed-charge nanoparticles for long circulation, low reticuloendothelial system clearance, and high tumor accumulation. Adv. Healthcare Mater. 2014, 3, 1439–1447.
[118]	Silva, V.L.; Al-Jamal, W.T. Exploiting the cancer niche: Tumor-associated macrophages and hypoxia as promising synergistic targets for nano-based therapy. J. Control. Release. 2017, 253, 82–96.
[119]	Leung, S.L.; Zha, Z.B.; Cohn, C.; Dai, Z.F.; Wu, X.Y. Anti-EGFR antibody conjugated organic-inorganic hybrid lipid nanovesicles selectively target tumor cells. Colloids Surf. B Biointerfaces. 2014, 121, 141–149.
[120]	Sun, B.F.; Deng, C.; Meng, F.H.; Zhang, J.; Zhong, Z.Y. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials. Acta Biomater. 2016, 45, 223–233.
[121]	Leamon, C.P.; Cooper, S.R.; Hardee, G.E. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug. Chem. 2003, 14, 738–747.
[122]	Lu, W.; Xiong, C.Y.; Zhang, R.; Shi, L.F.; Huang, M.; Zhang, G.D.; Song, S.L.; Huang, Q.; Liu, G.Y.; Li, C. Receptor-mediated transcytosis: a mechanism for active extravascular transport of nanoparticles in solid tumors. J. Control. Release. 2012, 161, 959–966.
[123]	Zhang, L.; Hao, P.Y.; Yang, D.J.; Feng, S.; Peng, B.; Appelhans, D.; Zhang, T.H.; Zan, X.J. Designing nanoparticles with improved tumor penetration: surface properties from the molecular architecture viewpoint. J. Mater. Chem. B. 2019, 7, 953–964.
[124]	Saha, K.; Rahimi, M.; Yazdani, M.; Kim, S.T.; Moyano, D.F.; Hou, S.; Das, R.; Mout, R.; Rezaee, F.; Mahmoudi, M.; Rotello, V.M. Regulation of macrophage recognition through the interplay of nanoparticle surface functionality and protein corona. ACS Nano. 2016, 10, 4421–4430.
[125]	Yan, Y.; Gause, K.T.; Kamphuis, M.M.J.; Ang, C.S.; O’brien-Simpson, N.M.; Lenzo, J.C.; Reynolds, E.C.; Nice, E.C.; Caruso, F. Differential roles of the protein corona in the cellular uptake of nanoporous polymer particles by monocyte and macrophage cell lines. ACS Nano. 2013, 7, 10960–10970.
[126]	Yang, M.Y.; Yu, L.X.; Guo, R.W.; Dong, A.J.; Lin, C.G.; Zhang, J.H. A modular coassembly approach to all-in-one multifunctional nanoplatform for synergistic codelivery of doxorubicin and curcumin. Nanomaterials. 2018, 8, 167.
[127]	Zhang, M.K.; Wang, X.G.; Zhu, J.Y.; Liu, M.D.; Li, C.X.; Feng, J.; Zhang, X.Z. Double-targeting explosible nanofirework for tumor ignition to guide tumor-depth photothermal therapy. Small. 2018, 14, 1800292.
[128]	Wang, J. Spatial targeting of tumor-associated macrophage and tumor cells with a designer nanocarrier for cancer chemo-immunotherapy. Annu. Int. Conf. IEEE Eng. Med. Biol. Soc. 2017, 291.
[129]	Thoma, C.R.; Zimmermann, M.; Agarkova, I.; Kelm, J.M.; Krek, W. 3D cell culture systems modeling tumor growth determinants in cancer target discovery. Adv. Drug Deliv. Rev. 2014, 69/70, 29–41.
[130]	Christina, V.; Gabriel, H.; Bruce, G.; Francesco, P. A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design. PLoS One. 2015, 10, e0118977.
[131]	Ozcelikkale, A.; Moon, H.R.; Linnes, M.; Han, B. In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles. Wiley Interdisciplinary Rev. Nanomed. Nanobiotechnology. 2017, e1460.